Membrane protein integrated technologies development for drug design
The aim of the ProMeTeus Consortium is to provide high-quality multidisciplinary knowledge through training and research on the development of protein studies as molecular tools for drug development and drug delivery. The focus of...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BES-2009-014440
ESTUDIO DE INTERACCIONES FUNCIONALMENTE RELEVANTES EN PROTEI...
43K€
Cerrado
PTQ-10-02770
NUEVAS TECNOLOGÍAS DE DESARROLLO DE PROTEÍNAS TERAPÉUTICAS
75K€
Cerrado
BFU2009-08401
EXPRESION, PLEGAMIENTO Y DINAMICA DE PROTEINAS DE MEMBRANA
206K€
Cerrado
RAMP
RAtionalising Membrane Protein crystallisation
3M€
Cerrado
BES-2017-080360
QUIMICA SUPRAMOLECULAR Y DINAMICA DE PEPTIDOS CICLICOS PARA...
93K€
Cerrado
CYCLOTIDE MECHANISM
Elucidating the mechanism of action of cyclotides ultra sta...
223K€
Cerrado
Información proyecto ProMeTeus
Duración del proyecto: 62 meses
Fecha Inicio: 2018-10-04
Fecha Fin: 2023-12-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The aim of the ProMeTeus Consortium is to provide high-quality multidisciplinary knowledge through training and research on the development of protein studies as molecular tools for drug development and drug delivery. The focus of the action is the creation of a synergistic pipeline to yield target membrane protein structures and characterization and bioactive molecules design, harnessing the complementary skills from Academic and SME participants. We propose to join key expertise in protein structural biology and biochemistry with state-of-the art facilities for membrane protein high-throughput target selection and expression. A strategic contribution will be provided by SME in key technologies (virtual screening, detergent science, organic synthesis and biotech) and in exploitation, dissemination and resource acquisition skills. We will deliver crucial data for the development of new leads for health issues such as the design of new antibiotics or new strategies for theranostics and foster a synergistic approach to novel bioactive compounds development between academic and SME. The acquisition of new skill from staff will come from secondments aimed at training on research topics not available at the home institutions and attendance to courses, workshops, seminar and conferences. In an era where academic institutions are called to participate actively in technological and industrial development and SME provide services to and benefit of the wide breadth of academic research programs, we will foster a culture of synergistic exchange and cross-fertilization.
The consortium consists of 9 beneficiaries and 2 partners , of which 7 are academic and 4 are SME. During 4 years 16 ESRs, 6 ERs and 2 research managers will be seconded to 1 Institutions, where they will be supported by a team of leading scientists. The Network will promote the integration of academic and SME in combining excellent science with entrepreneurial approach and high-throughput methodologies.